Complement in Sickle Cell Disease: Are We Ready for Prime Time?

References

• Maitra P, Caughey M, Robinson L, et al. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica. 2017;102(4):626–636. doi:10.3324/haematol.2016.153791
   PubMed Web of Science ®Google Scholar
• Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019;14(1):263–292. doi:10.1146/annurev-pathmechdis-012418-012838
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364(9442):1343–1360. doi:10.1016/S0140-6736(04)17192-4
   PubMed Web of Science ®Google Scholar
• Kim K, Li J, Barazia A, et al. ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease. Haematologica. 2017;102:246–259. doi:10.3324/haematol.2016.151159
   Web of Science ®Google Scholar
• Lamarre Y, Romana M, Waltz X, et al. Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease. Haematologica. 2012;97:1641–1647. doi:10.3324/haematol.2012.066670
   PubMed Web of Science ®Google Scholar
• Allali S, Maciel TT, Hermine O, de Montalembert M. Innate immune cells, major protagonists of sickle cell disease pathophysiology. Haematologica. 2020;105(2):273–283. doi:10.3324/haematol.2019.229989
   PubMed Web of Science ®Google Scholar
• Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
   PubMed Web of Science ®Google Scholar
• Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257.
   PubMed Web of Science ®Google Scholar
• Chudwin DS, Papierniak C, Lint TF, Korenblit AD. Activation of the alternative complement pathway by red blood cells from patients with sickle cell disease. Clin Immunol. 1994;71(2):199–202.
   Web of Science ®Google Scholar
• Mold C, Tamerius JD, Phillips G. Complement activation during painful crisis in sickle cell anemia. Clin Immunol Immunopathol. 1995;76(3):314–320. doi:10.1006/clin.1995.1131
   Google Scholar
• Gavriilaki E, Mainou M, Christodoulou I, et al. In vitro evidence of complement activation in patients with sickle cell disease. Haematologica. 2017;102(12):e481. doi:10.3324/haematol.2017.174201
   PubMed Web of Science ®Google Scholar
• Roumenina LT, Chadebech P, Bodivit G, et al. Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol. 2020;95(5):456–464. doi:10.1002/ajh.25742
   PubMed Web of Science ®Google Scholar
• Chudwin DS, Korenblit AD, Kingzette M, Artrip S, Rao S. Increased activation of the alternative complement pathway in sickle cell disease. Clin Immunol Immunopathol. 1985;37(1):93–97. doi:10.1016/0090-1229(85)90139-4
   Google Scholar
• Lombardi E, Matte A, Risitano AM, et al. Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule. Haematologica. 2019;104:919–928. doi:10.3324/haematol.2018.198622
   PubMed Web of Science ®Google Scholar
• Vaught AJ, Gavriilaki E, Hueppchen N, et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol. 2016;44:390–398. doi:10.1016/j.exphem.2016.01.005
   PubMed Web of Science ®Google Scholar
• Brady TM, Pruette C, Loeffler LF, et al. Typical Hus: evidence of acute phase complement activation from a daycare outbreak. J Clin Exp Nephrol. 2016;1(2). doi:10.21767/2472-5056.100011
   PubMedGoogle Scholar
• Gavriilaki E, Chrysanthopoulou A, Sakellari I, et al. Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy. Thromb Haemost. 2019;119(09):1433–1440. doi:10.1055/s-0039-1692721
   Web of Science ®Google Scholar
• Chaturvedi S, Braunstein EM, Yuan X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239–251. doi:10.1182/blood.2019003863
   PubMed Web of Science ®Google Scholar
• Gavriilaki E, Gkaliagkousi E, Grigoriadis S, Anyfanti P, Douma S, Anagnostopoulos A. Hypertension in hematologic malignancies and hematopoietic cell transplantation: an emerging issue with the introduction of novel treatments. Blood Rev. 2019;35:51–58. doi:10.1016/j.blre.2019.03.003
   Web of Science ®Google Scholar
• Gavriilaki E, Touloumenidou T, Sakellari I, et al. Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy. Thromb Haemost. 2020;120(04):638–646. doi:10.1055/s-0040-1702225
   Web of Science ®Google Scholar
• Gavriilaki E, Christodoulou I, Koravou EE, et al. Pre- and post-transfusion complement activation in transfusion-dependent beta-thalassaemia. Hemasphere. 2018;2:e58. doi:10.1097/HS9.0000000000000058
   Web of Science ®Google Scholar
• Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644. doi:10.1056/NEJM199406093302303
   PubMed Web of Science ®Google Scholar
• Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003;123:359–365. doi:10.1046/j.1365-2141.2003.04594.x
   PubMed Web of Science ®Google Scholar
• Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42(1–3):23–30. doi:10.1016/S0162-3109(99)00007-7
   PubMed Web of Science ®Google Scholar
• Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ, Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun. 2000;68(2):688–693. doi:10.1128/IAI.68.2.688-693.2000
   PubMed Web of Science ®Google Scholar
• Francis WG, Womack CR. Serum complement activity in normal individuals and patients with sickle cell hemoglobin abnormalities. Am J Med Technol. 1967;33:77–86.
   Google Scholar
• Johnston RB, Newman SL, Struth AG. An abnormality of the alternate pathway of complement activation in sickle-cell disease. N Engl J Med. 1973;288(16):803–808. doi:10.1056/NEJM197304192881601
   PubMed Web of Science ®Google Scholar
• Wilson WA, Hughes GR, Lachmann PJ. Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J. 1976;1:367–369. doi:10.1136/bmj.1.6006.367
   PubMed Web of Science ®Google Scholar
• deCiutiis AC, Peterson CM, Polley MJ, Metakis LJ. Alternative pathway activation in sickle cell disease and beta-thalassemia major. J Natl Med Assoc. 1978;70:503–506.
   Google Scholar
• Larcher VF, Wyke RJ, Davis LR, Stroud CE, Williams R. Defective yeast opsonisation and functional deficiency of complement in sickle cell disease. Arch Dis Child. 1982;57:343–346. doi:10.1136/adc.57.5.343
   PubMed Web of Science ®Google Scholar
• Koethe SM, Casper JT, Rodey GE. Alternative complement pathway activity in sera from patients with sickle cell disease. Clin Exp Immunol. 1976;23:56–60.
   PubMed Web of Science ®Google Scholar
• Wang RH, Phillips G Jr, Medof ME, Mold C. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest. 1993;92:1326–1335. doi:10.1172/JCI116706
   PubMed Web of Science ®Google Scholar
• Wilson WA, Thomas EJ, Sissons JG. Complement activation in asymptomatic patients with sickle cell anaemia. Clin Exp Immunol. 1979;36:130–139.
   PubMed Web of Science ®Google Scholar
• Test ST, Woolworth VS. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation. Blood. 1994;83(3):842. doi:10.1182/blood.V83.3.842.842
   PubMed Web of Science ®Google Scholar
• Merle NS, Grunenwald A, Rajaratnam H, et al. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018;3. doi:10.1172/jci.insight.96910
   Web of Science ®Google Scholar
• Vercellotti GM, Dalmasso AP, Schaid TR Jr, et al. Critical role of C5a in sickle cell disease. Am J Hematol. 2019;94(3):327–337. doi:10.1002/ajh.25384
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Gavriilaki E, Vasileiadis I, et al. Endothelial microvesicles circulating in peripheral and coronary circulation are associated with central blood pressure in coronary artery disease. Am J Hypertens. 2019;32(12):1199–1205. doi:10.1093/ajh/hpz116
   PubMed Web of Science ®Google Scholar
• Gkaliagkousi E, Nikolaidou B, Gavriilaki E, et al. Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. Diabetes Vascular Dis Res. 2019;16(5):458–465. doi:10.1177/1479164119844691
   PubMed Web of Science ®Google Scholar
• de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood. 2001;98(3):860–867. doi:10.1182/blood.V98.3.860
   PubMed Web of Science ®Google Scholar
• Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750–760. doi:10.1172/JCI89741
   PubMed Web of Science ®Google Scholar
• Beckman JD, Abdullah F, Chen C, et al. Endothelial TLR4 expression mediates vaso-occlusive crisis in sickle cell disease. Front Immunol. 2021;11:613278. doi:10.3389/fimmu.2020.613278
   Web of Science ®Google Scholar
• Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383–1389. doi:10.1038/nm1202-799
   PubMed Web of Science ®Google Scholar
• Camus SM, De Moraes JA, Bonnin P, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015;125(24):3805–3814. doi:10.1182/blood-2014-07-589283
   PubMed Web of Science ®Google Scholar
• Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809–4820. doi:10.1172/JCI64578
   PubMed Web of Science ®Google Scholar
• Adisa OA, Hu Y, Ghosh S, Aryee D, Osunkwo I, Ofori-Acquah SF. Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J Haematol. 2013;162(5):702–705. doi:10.1111/bjh.12445
   Web of Science ®Google Scholar
• Pfefferle M, Ingoglia G, Schaer CA, et al. Hemolysis transforms liver macrophages into antiinflammatory erythrophagocytes. J Clin Invest. 2020;130(10):5576–5590. doi:10.1172/JCI137282
   Web of Science ®Google Scholar
• Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201(6):871–879. doi:10.1084/jem.20041497
   PubMed Web of Science ®Google Scholar
• Merle NS, Paule R, Leon J, et al. P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proc Natl Acad Sci U S A. 2019;116(13):6280–6285. doi:10.1073/pnas.1814797116
   PubMed Web of Science ®Google Scholar
• Ruiz-Delgado GJ, Vazquez-Garza E, Mendez-Ramirez N, Gomez-Almaguer D. Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria. Hematology. 2009;14(1):33–37. doi:10.1179/102453309X385089
   PubMed Web of Science ®Google Scholar
• Asimakopoulos JV, Terpos E, Papageorgiou L, et al. The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. Med Sci Monit. 2014;20:123–139. doi:10.12659/MSM.889727
   Web of Science ®Google Scholar
• Sartain SE, Turner NA, Moake JL. TNF regulates essential alternative complement pathway components and impairs activation of protein C in human glomerular endothelial cells. J Immunol. 2016;196(2):832–845. doi:10.4049/jimmunol.1500960
   Web of Science ®Google Scholar
• Salama MA, Sadek NA, Hassab HM, Abadeer AF, Mikhael IL. Erythrocyte autoantibodies and expression of CD59 on the surface of red blood cells of polytransfused patients with beta-thalassaemia major. Br J Biomed Sci. 2004;61:88–92. doi:10.1080/09674845.2004.11732650
   PubMed Web of Science ®Google Scholar
• Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703–711. doi:10.1016/0092-8674(93)90250-T
   PubMed Web of Science ®Google Scholar
• Chapin J, Terry HS, Kleinert D, Laurence J. The role of complement activation in thrombosis and hemolytic anemias. Transfus Apher Sci. 2016;54(2):191–198. doi:10.1016/j.transci.2016.04.008
   PubMed Web of Science ®Google Scholar
• Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185(9):5628–5636. doi:10.4049/jimmunol.0903678
   PubMed Web of Science ®Google Scholar
• Zecher D, Cumpelik A, Schifferli JA. Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement. Arterioscler Thromb Vasc Biol. 2014;34(2):313–320. doi:10.1161/ATVBAHA.113.302378
   PubMed Web of Science ®Google Scholar
• Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12(6):682–687. doi:10.1038/nm1419
   Web of Science ®Google Scholar
• Hebbel RP, Belcher JD, Vercellotti GM. The multifaceted role of ischemia/reperfusion in sickle cell anemia. J Clin Invest. 2020;130(3):1062–1072. doi:10.1172/JCI133639
   PubMed Web of Science ®Google Scholar
• Riedemann NC, Ward PA. Complement in ischemia reperfusion injury. Am J Pathol. 2003;162(2):363–367. doi:10.1016/S0002-9440(10)63830-8
   Web of Science ®Google Scholar
• Farrar CA, Asgari E, Schwaeble WJ, Sacks SH. Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol. 2012;3:341. doi:10.3389/fimmu.2012.00341
   PubMed Web of Science ®Google Scholar
• Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clin Exp Immunol. 2021;203(1):96–104. doi:10.1111/cei.13497
   PubMed Web of Science ®Google Scholar
• Rai P, Ataga K. Drug therapies for the management of sickle cell disease. F1000Research. 2020;9:592. doi:10.12688/f1000research.22433.1
   Google Scholar
• Baliga B, Pace B, Chen H, Shah A, Yang Y. Mechanisms for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. AJH. 2000;65(3):227–233.
   Google Scholar
• Agrawal RK, Patel RK, Shah V, et al. Hydroxyurea in Sickle Cell Disease: drug Review. Indian J Hematol Blood Transfus. 2014;30(2):91–96. doi:10.1007/s12288-013-0261-4
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi:10.1056/NEJM199505183322001
   PubMed Web of Science ®Google Scholar
• Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996;129(4):559–565. doi:10.1016/S0022-3476(96)70121-X
   PubMed Web of Science ®Google Scholar
• Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139(6):790–796. doi:10.1067/mpd.2001.119590
   PubMed Web of Science ®Google Scholar
• Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS study. J Pediatr. 2002;140(2):225–229. doi:10.1067/mpd.2002.121383
   PubMed Web of Science ®Google Scholar
• Hankins JS, Ware RE, Rogers ZR, et al. Longterm hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106(7):2269–2275. doi:10.1182/blood-2004-12-4973
   PubMed Web of Science ®Google Scholar
• Ryan K, Heeney M. New England pediatric sickle cell consortium. 2004.
   Google Scholar
• Sadaf A, Quinn CT. L-glutamine for sickle cell disease: knight or pawn? Exp Biol Med. 2020;245(2):146–154. doi:10.1177/1535370219900637
   Web of Science ®Google Scholar
• Cox SE, Hart E, Kirkham FJ, Stotesbury H. L-Glutamine in sickle cell disease. Drugs Today. 2020;56(4):257–268. doi:10.1358/dot.2020.56.4.3110575
   PubMed Web of Science ®Google Scholar
• AlDallal SM. Voxelotor: a ray of hope for sickle disease. Cureus. 2020;12(2):e7105.
   Web of Science ®Google Scholar
• Prescribing information for Adakveo (crizanlizumab): US food and drug administration; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf. Accessed March 16, 2021.
   Google Scholar
• Thom H, Jansen J, Shafrin J, et al. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. BMJ Open. 2020;10(9):e034147. doi:10.1136/bmjopen-2019-034147
   PubMed Web of Science ®Google Scholar
• Parkman R. The application of bone marrow transplantation to the treatment of genetic diseases. Science. 1986;232(4756):1373–1378. doi:10.1126/science.3520819
   PubMed Web of Science ®Google Scholar
• Brodsky RA, DeBaun MR. Are genetic approaches still needed to cure sickle cell disease? J Clin Invest. 2020;130(1):7–9. doi:10.1172/JCI133856
   Web of Science ®Google Scholar
• Ferrone F, Nagel RL, et al. Polymer structure and polymerization of deoxyhemoglobin S. In: Steinberg MH, Forget BG, Higgs DR, editors. Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management. Cambridge, UK: Cambridge University Press; 2001.
   Google Scholar
• Morrone K, Mitchell WB, Manwani D. Novel sickle cell disease therapies: targeting pathways downstream of sickling. Semin Hematol. 2018;55(2):68–75. doi:10.1053/j.seminhematol.2018.04.007
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi:10.1056/NEJMoa061648
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847. doi:10.1182/blood-2007-06-094136
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540–549. doi:10.1182/blood-2018-09-876805
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong lee lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539. doi:10.1182/blood-2018-09-876136
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181. doi:10.1056/NEJMoa1208981
   PubMed Web of Science ®Google Scholar
• Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangiopathies: unraveling ariadne’s thread into the labyrinth of complement therapeutics. Front Immunol. 2019;10:337. doi:10.3389/fimmu.2019.00337
   PubMed Web of Science ®Google Scholar
• Yuan X, Gavriilaki E, Thanassi JA, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017;102(3):466–475. doi:10.3324/haematol.2016.153312
   PubMed Web of Science ®Google Scholar
• Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26–47. doi:10.1038/nrneph.2017.156
   PubMed Web of Science ®Google Scholar
• Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062–1064. doi:10.1182/blood-2015-09-669770
   PubMed Web of Science ®Google Scholar
• Vlachaki E, Gavriilaki E, Kafantari K, et al. Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibition. Hemoglobin. 2018;42(5–6):339–341. doi:10.1080/03630269.2018.1540353
   PubMed Web of Science ®Google Scholar
• Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015;55(10):2398–2403. doi:10.1111/trf.13144
   PubMed Web of Science ®Google Scholar
• Chonat S, Quarmyne MO, Bennett CM, et al. Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2018;103(10):e483–e485. doi:10.3324/haematol.2018.194670
   PubMed Web of Science ®Google Scholar
• Kirui Chebet L, Scully M, Mcqueen N, Porter J, Elftheriou P. Use of eculizumab for the treatment of hyperhaemolysis in pregnancy in sickle cell disease: a case report. Blood. 2018;132(Supplement 1):4922. doi:10.1182/blood-2018-99-118396
   Web of Science ®Google Scholar
• Floch A, Morel A, Zanchetta-Balint F, et al. Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease. Haematologica. 2020;105(11):2694–2697. doi:10.3324/haematol.2020.253856
   Web of Science ®Google Scholar
• Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327–355. doi:10.1182/bloodadvances.2019001143
   PubMed Web of Science ®Google Scholar
• Chonat S, Graciaa S, Shin HS, et al. Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease. Haematologica. 2020;105(12).
   Web of Science ®Google Scholar
• Azul M, Shah S, Williams S, Vercellotti GM, Boucher AA. Evidence for complement-mediated bone marrow necrosis in a young adult with sickle cell disease. Blood Cells Mol Dis. 2021;86:102508. doi:10.1016/j.bcmd.2020.102508
   Web of Science ®Google Scholar
• Jodele S. Double trouble: complement-mediated thrombotic microangiopathy in patients with hemoglobinopathies after stem cell transplantation. Pediatr Blood Cancer. 2017;64(9):e26566. doi:10.1002/pbc.26566
   Web of Science ®Google Scholar
• Chonat S, Chandrakasan S, Kalinyak KA, et al. Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab. Br J Haematol. 2016;175(4):744–747. doi:10.1111/bjh.13884
   Web of Science ®Google Scholar
• Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45(4):423–440. doi:10.1111/eci.12419
   PubMed Web of Science ®Google Scholar
• Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology. 2020;215:108450.
   PubMed Web of Science ®Google Scholar
• Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol. 2020;189(6). doi:10.1111/bjh.16783
   Web of Science ®Google Scholar
• Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5). doi:10.1128/mBio.01753-18
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao G, Song N, et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4 transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(77):1–12. doi:10.1038/s41426-018-0063-8
   Web of Science ®Google Scholar
• Diurno F, Numis FG, Porta G, et al. Facchini, Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24:4040–4047. doi:10.26355/eurrev_202004_20875
   PubMed Web of Science ®Google Scholar
• Ochocinski D, Dalal M, Black LV, et al. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Front Pediatr. 2020;8:38. doi:10.3389/fped.2020.00038
   PubMed Web of Science ®Google Scholar
• McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737. doi:10.15585/mmwr.mm6627e1
   PubMed Web of Science ®Google Scholar